-+ 0.00%
-+ 0.00%
-+ 0.00%

AT ASH 2025 ORAL PRESENTATION, IMMIX BIOPHARMA REPORTS POSITIVE PHASE 2 NXC-201 RESULTS, ADVANCING TOWARD BLA SUBMISSION AS A POTENTIALLY FIRST- AND BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

Reuters·12/07/2025 23:15:00

Please log in to view news